Anavex Life Sciences Corp

AVXL remains entrenched in a Stage 4 decline with active lower highs and lower lows under declining EMAs. Both medium-term and long-term directional biases are bearish, and with price trading near support and below key EMAs, execution should be deferred until rallies into the declining 9/21 EMA resistance zone for a rejection-based trim entry.

• ↑AD/PD 2026 data: blarcamesine preserved brain volume in early Alzheimer’s.
• ↑Median analyst target of $20 implies ~640% upside from $2.70.
• ↓Earnings yield of -2.86% and lack of positive cash flow.